key: cord-0894207-w2ltw9w4
authors: Chiba, Shiho; Kiso, Maki; Nakajima, Noriko; Iida, Shun; Maemura, Tadashi; Kuroda, Makoto; Sato, Yuko; Ito, Mutsumi; Okuda, Moe; Yamada, Shinya; Iwatsuki-Horimoto, Kiyoko; Watanabe, Tokiko; Imai, Masaki; Armbrust, Tammy; Baric, Ralph S.; Halfmann, Peter J.; Suzuki, Tadaki; Kawaoka, Yoshihiro
title: Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
date: 2022-02-01
journal: mBio
DOI: 10.1128/mbio.03044-21
sha: 4ba793f317ce6e3c1a5c2190d6433a2a1ace7f4a
doc_id: 894207
cord_uid: w2ltw9w4

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since December 2019, causing coronavirus disease 2019 (COVID-19). Although vaccines for this virus have been developed rapidly, repurposing drugs approved to treat other diseases remains an invaluable treatment strategy. Here, we evaluated the inhibitory effects of drugs on SARS-CoV-2 replication in a hamster infection model and in in vitro assays. Favipiravir significantly suppressed virus replication in hamster lungs. Remdesivir inhibited virus replication in vitro, but was not effective in the hamster model. However, GS-441524, a metabolite of remdesivir, effectively suppressed virus replication in hamsters. Co-administration of favipiravir and GS-441524 more efficiently reduced virus load in hamster lungs than did single administration of either drug for both the prophylactic and therapeutic regimens; prophylactic co-administration also efficiently inhibited lung inflammation in the infected animals. Furthermore, pretreatment of hamsters with favipiravir and GS-441524 effectively protected them from virus transmission via respiratory droplets upon exposure to infected hamsters. Repurposing and co-administration of antiviral drugs may help combat COVID-19.

variants have emerged which are antigenically advanced and/or have greater replication fitness than the original virus. More than 4.5 million global deaths have been reported to date. Several vaccines with different modalities have been approved and rapidly distributed across numerous countries; however, given that escape variants continue to appear, there remains an urgent need to establish COVID-19 treatment regimens by repurposing drugs currently approved to treat other infections or diseases. Several drugs, including favipiravir and remdesivir, which are approved for the treatment of other diseases have been tested for efficacy against SARS-CoV-2 in clinical trials (1) (2) (3) (4) (5) (6) (7) . For remdesivir, some reports, including meta-analyses, have shown marked clinical improvements, such as shorter recovery times, with remdesivir treatment compared to placebo (4, 6, 8, 9) , although statistical significance was not always achieved (4, 5, 7) . It is important to note that clinical trials such as these are limited in that they are generally not designed to evaluate the effects of drugs on virus load in patients under different conditions. In contrast, animal models, in which various experimental conditions can be tested, can advance our understanding of the effectiveness of potential drug therapies. Syrian hamsters are highly susceptible to the virus and an excellent model of SARS-CoV-2 infection (10) (11) (12) (13) (14) (15) . Utilizing this model, investigators have shown that favipiravir administration inhibits virus replication and inflammation in the lungs and have examined the pharmacokinetics of the drug in vivo (13, 14) . In the direct-contact transmission model, high-dose favipiravir pretreatment of a naive animal that was then co-housed with an infected animal significantly reduced the virus titers in the lungs (14) . Here, we found that co-administration of favipiravir and GS-441524, a metabolite of remdesivir, more potently reduced virus load and inflammation in the lungs of infected hamsters than either favipiravir or GS-441524 alone. Furthermore, by using a setup that allows only airborne transmission without direct contact between animals, we demonstrated that co-administration of these drugs to naive animals protected them, albeit not completely, from airborne virus transmission. These results suggest the feasibility of co-administering these repurposed drugs as a treatment option for COVID-19.

Effects of approved drugs on SARS-CoV-2 replication in the hamster model and in vitro. We first examined whether drugs that are currently approved for COVID-19 or other diseases have inhibitory effects on SARS-CoV-2 replication in Syrian hamsters. One day prior to SARS-CoV-2 challenge (day -1), hamsters were prophylactically administered favipiravir, lopinavir/ritonavir, nelfinavir, hydroxychloroquine sulfate, remdesivir (GS-5734), ciclesonide, nafamostat mesylate, ivermectin, mefloquine, umifenovir, or cepharanthine (see regimens in Table S1 in the supplemental material), and were then intranasally infected with 10 PFU/animal of SARS-CoV-2 (day 0). Body weight was monitored daily as a clinical symptom marker, and on day 4 postinfection, lungs and nasal turbinates were sampled to examine infectious virus titers in plaque assays. Administration of lopinavir/ritonavir, nelfinavir, hydroxychloroquine sulfate, remdesivir (GS-5734), ciclesonide, nafamostat mesylate, ivermectin, mefloquine, umifenovir, or cepharanthine did not significantly affect virus replication in these organs, or body weights, under these experimental conditions (Fig. S1A-X) ; the findings for hydroxychloroquine sulfate and lopinavir/ritonavir are consistent with previous studies in hamster and mouse models, respectively (14, 16, 17) .

In contrast, favipiravir, which was first approved as an antiviral for influenza virus treatment in Japan, significantly reduced virus replication in the lungs of hamsters challenged with a low (10 PFU) or high dose (1,000 PFU) of SARS-CoV-2 ( Fig. 1A and B; the mean virus load was reduced to 12.8% or 29.2% of the vehicle control group, with 10 or 1,000 PFU of challenge virus, respectively) when given as a prophylactic regimen (dosages on days -1 to 3: 300 mg/kg, twice/day). This is consistent with the findings of a previous study in hamsters (13, 14) and with findings in human clinical trials, which indicated that favipiravir can reduce recovery times for mild-to-moderate patients (3). Therapeutic administration of favipiravir (dosages on days 1 to 3: 300 mg/kg, twice/ day) also reduced virus titers in the lungs after a high-dose challenge (mean titer reduced to 22.4% of the control group), although not significantly after the lower dose (mean titer reduced to 62.9% of the control group; Fig. 1B ). Virus titers in the nasal turbinate were also slightly reduced, although a statistically significant difference was seen only with the therapeutic regimen and low-dose virus challenge (mean titer reduced to 18.9% of the control group; Fig. 1C ). Body weight changes were not improved by favipiravir treatment (Fig. S2 ) under these conditions.

To examine the inhibitory effects of these drugs on SARS-CoV-2 replication in vitro, we determined half-maximal effective concentrations (EC 50 ) and half-maximal inhibitory concentrations (IC 50 ) (Table S2) . Remdesivir effectively inhibited cytopathic effects (CPE) in VeroE6/TMPRSS2 and Calu-3 cells (EC 50 = 1.7 mM and 0.3 mM, respectively), with 2-to 3-log lower EC 50 values than those of favipiravir (EC 50 = 130 mM and 320 mM, respectively), although it did not significantly inhibit virus replication in hamsters ( Fig. S1D and E) . Nelfinavir, a protease inhibitor approved for the treatment of HIV infection, showed comparable suppressive efficacy to that of remdesivir, with effectiveness at ,10 mM under these in vitro conditions, despite its lack of efficacy in the hamster model ( Fig. S1A and B) . These results are consistent with those of some previous studies which have demonstrated the in vitro inhibitory efficacy of remdesivir (18) (19) (20) (21) (22) (23) (24) or nelfinavir (18, 20, (25) (26) (27) on SARS-CoV-2 replication.

Inhibitory effects of GS-441524 on SARS-CoV-2 replication in the hamster model. The inhibitory effects of remdesivir on SARS-CoV-2 replication observed in vitro prompted us to evaluate the in vivo effects of GS-441524, a metabolite of remdesivir. Although GS-441524 is not currently approved for clinical use for humans, its efficacy Each group of hamsters (n = 4) was administered vehicle control or favipiravir (300 mg/kg) as a prophylactic (days -1 to 3; twice/day) or therapeutic regimen (days 1 to 3; twice/day). The hamsters were intranasally inoculated with 10 or 1,000 PFU of SARS-CoV-2 (day 0). Infectious virus titers (PFU/g) in the lungs (panel B) and nasal turbinate (panel C) were examined by performing plaque assays. Dots and bars show the value for each animal and the average in each group, respectively (n = 4, mean 6 SD [standard deviation of the mean]). *, P , 0.05; NS, not significant; determined by a one-way analysis of variance (ANOVA) and corrected for multigroup comparison using Dunnett's test.

has been shown for feline coronavirus (28, 29) . Hamsters were administered GS-441524 either prophylactically (days -1 to 3: 25 mg/kg, twice/day) or therapeutically (days 1 to 3: 25 mg/kg, twice/day), or were administered vehicle control, and were then infected with SARS-CoV-2 on day 0. Infectious viral load in the lungs on day 4 postinfection was significantly reduced by both prophylactic and therapeutic regimens in both low-dose (10 PFU) and high-dose (1,000 PFU) virus infections ( Fig. 2A) , With the prophylactic regimen, mean viral loads in the lungs were reduced to 15.9% or 9.9% of that of the vehicle control group with low-or high-dose virus infection, respectively; with the therapeutic regimen, mean viral loads were reduced to 21.3% or 20.4% of that of the vehicle control group with low-or high-dose virus infection, respectively. Virus replication in the nasal turbinate and body weight loss were not significantly affected by the treatment (Fig. 2B, Fig. S3 ).

Co-administration of GS-441524 and favipiravir suppresses SARS-CoV-2 replication in vivo. We also tested co-administration of favipiravir and GS-441524 in the same hamster model. Both the prophylactic (days -1 to 3; twice/day) and the therapeutic (days 1 to 3; twice/day) co-administration regimens inhibited virus replication in the lungs more drastically than either favipiravir or GS-441524 alone, reducing the viral loads on day 4 by 2 log-fold compared to those in the vehicle control-treated animals (Fig. 3A) . Virus replication in the nasal turbinates was also inhibited by prophylactic or therapeutic treatment in the high-dose virus challenge, though there was not always significant difference (Fig. 3B ). Body weight was not affected by treatment (Fig. S4 ). To directly compare the effects of favipiravir or GS-441524 treatment alone or in combination side-by-side, we examined the effectiveness of each therapeutic regimen after a 1,000-PFU virus challenge ( Fig. 3C-E) . Co-administration of favipiravir and GS-441524 reduced virus titers effectively in both the lungs (Fig. 3C ) and the nasal turbinate ( Fig. 3D ) on day 4, although no statistically significant difference was seen compared to the favipiravir-treated group. Body weight change, which may reflect both disease severity and drug toxicity, was not significantly different between the vehicle-treated and drug-treated groups after virus infection (Fig. 3E ). To investigate whether the effects of favipiravir and GS-441524 are synergistic, we also tested the antiviral efficacy of the combination treatment in an in vitro plaque reduction assay (Fig. S5) . Although GS-441524 alone almost completely inhibited plaque formation at 3 mM, favipiravir alone did not show an antiviral effect within the concentration range that did not Each group of hamsters (n = 4) was administered vehicle control or GS-441524 (25 mg/kg) as a prophylactic (days -1 to 3; twice/day) or therapeutic regimen (days 1 to 3; twice/day). The hamsters were intranasally inoculated with 10 or 1,000 PFU of SARS-CoV-2 (day 0). Infectious virus titers (PFU/g) in the lungs (panel A) and nasal turbinate (panel B) were examined by performing plaque assays. Dots and bars show the value for each animal and the average in each group, respectively (n = 4, mean 6 SD). *, P , 0.05; NS, not significant; determined by a one-way analysis of variance (ANOVA) and corrected for multi-group comparison using Dunnett's test.

cause cytotoxicity (#300 mM; Fig. S5A ), which is consistent with the IC 50 analysis (Table S2 ). Synergy scores for the combination treatment were calculated using SynergyFinder (30) . The scores within -5 to 5 for all of the drug-dose combinations analyzed, and the summary synergy score of 0.136, suggest that there was no synergy between the two drugs under these in vitro conditions (Fig. S5B) .

The effect of co-administration of GS-441524 and favipiravir on pathogenicity in lungs. To evaluate the effect of co-administration of favipiravir and GS-441524 on lung pathology, lung sections from day 4 were histopathologically analyzed (Fig. 4) and an inflammation score for each pulmonary lobe was determined according to the criteria described in Materials and Methods (Table S3 ). The lung sections from the therapeutic co-administration group (days 1 to 3: twice daily) and the vehicle control group ( Fig. 4B and C, respectively) showed extensive inflammatory cell infiltration, mainly in the peri-bronchial regions; this infiltration was observed in more than 20% of the lung sections, with no obvious difference between the therapeutic co-administration and vehicle control groups. In contrast, the lung sections from the prophylactic co- Each group of hamsters (n = 4) was administered vehicle control or the combination of favipiravir (300 mg/kg) and GS-441524 (25 mg/kg) as a prophylactic regimen (days -1 to 3; twice/day) or a therapeutic regimen (days 1 to 3; twice/day). The hamsters were intranasally inoculated with 10 or 1,000 PFU of SARS-CoV-2 (day 0). Infectious virus titers (PFU/g) in the lungs (panel A) and nasal turbinate (panel B) were examined by performing plaque assays. (C to E) Each group of hamsters (n = 3 for favipiravir treatment; n = 4 for other groups) was mock-infected or infected with 1,000 PFU of SARS-CoV-2 (day 0), and was administered vehicle control, favipiravir (300 mg/kg) GS-441524 (25 mg/kg), or a combination of both drugs as a therapeutic regimen (days 1 to 3; twice/day). Infectious virus titers (PFU/g) in the lungs (panel C) and nasal turbinate (panel D) were examined by performing plaque assays. Body weight change was monitored for 4 days (panel E; mean 6 SD). Dots and bars in panels A to D show the value for each animal and the average in each group, respectively (mean 6 SD). *, P , 0.05; NS, not significant; determined by a one-way analysis of variance (ANOVA) and corrected for multi-group comparison using Dunnett's test.

Favipiravir and GS-441524 in SARS-CoV-2 Hamster Model ® administration group (days -1 to 3: twice daily) or the mock animals showed only limited numbers of small foci of inflammatory cell infiltration or no inflammation, respectively ( Fig. 4A and D, respectively). In the prophylactic and therapeutic co-administration groups, viral RNA signals, which were specifically detected by in situ hybridization, were detected only in relatively limited regions of the lung sections, with no obvious difference between the two groups ( Fig. 4E and F, respectively). In contrast, in the vehicle control group, viral RNA signals were detected across more extended regions (Fig. 4G ) compared to those of the groups treated with either drug regimen ( Fig. 4E and F). Notably, immunohistochemistry for SARS-CoV-2 antigen nucleocapsid protein revealed that virus antigens were present in bronchial and alveolar epithelial cells in each group with virus infection, regardless of the presence or absence of drugs or the timing of administration, and there were no clear differences in the number of virus antigen-positive cells between the co-administration groups (prophylactic and therapeutic; Fig. 4I and J, respectively) and the vehicle control groups (Fig. 4K ). Taken together, in comparison to the vehicle control group, the prophylactic co-administration group had reduced viral spread and inflammation in the lungs, whereas the therapeutic co-administration group had reduced viral spread in the lungs but no difference in pulmonary inflammation on day 4.

Protective efficacy of GS-441524 and favipiravir pretreatment of hamsters in the transmission model. Finally, we examined whether pretreatment with GS-441524 and/or favipiravir could protect animals from SARS-CoV-2 infection, using the hamster transmission model (31) . Naive hamsters (exposed animals) were administered favipiravir (300 mg/kg) and/or GS-441524 (25 mg/kg), or vehicle control, twice/day (n = 6/ group); another group of animals (infected animals) was inoculated with 1,000 PFU of SARS-CoV-2 Spike-D614G virus, a variant with the single mutation D614G in the Spike protein, which results in higher transmissibility than that of the original Wuhan virus (31). One day after initiating drug treatment of the exposed animals and virus inoculation of the infected group, each exposed animal was paired with one of the infected animals with a 5-cm gap between their cages, allowing only airborne viral transmission between animals ( Fig. 5A and B) . On day 4 post-exposure, the exposed animals were euthanized to titrate the virus loads in the nasal turbinate and lungs. The organs of infected animals were also titrated to confirm virus replication on day 4 postinfection (Fig. 5C; lower panel) . For the vehicle control group, the nasal turbinate and lungs of all exposed animals showed high virus titers, underscoring the high transmissibility of the virus between the hamsters (Fig. 5C; upper left) . With favipiravir administration, the exposed animals showed lower virus loads, especially in the lungs, suggesting that favipiravir contributed to the retardation of transmission and/or inhibition of virus growth ( Fig. 5C; upper middle left) . With GS-441524 administration, the effect on viral load was more subtle (Fig. 5C ; upper middle right). With favipiravir or GS-441524 administration, virus transmission was not detected in 1 pair out of 6. Strikingly, with co-administration of favipiravir and GS-441524, 4 of the 6 exposed animals were Naive hamsters (exposed animals) were administered favipiravir (300 mg/kg) and/or GS-441524 (25 mg/kg) or vehicle control (days -1 to 3 post-exposure; twice/day; n = 6/group). Another group of animals (infected animals) was inoculated with 1,000 PFU of SARS-CoV-2 Spike-D614G variant. One day after the exposed animals began their treatment regimen, each exposed animal was paired with one of the infected animals with a 5-cm gap between their cages. Organs were harvested for virus titration on day 4 postinfection or day 4 post-exposure from infected or exposed animals, respectively. (C) Infectious virus titers (PFU/g) in the nasal turbinate and lungs on day 4 post-exposure (upper panel) or day 4 postinfection (lower panel) were examined by performing plaque assays. ND, not detected (limit of detection: 10 PFU/organ).

Favipiravir and GS-441524 in SARS-CoV-2 Hamster Model ® protected from virus transmission as of day 4 post-exposure, although this was not statistically significant compared with the vehicle control group (Fig. 5C ; upper right; Fisher's exact test; two-tailed P = 0.061).

In this study, we assessed the inhibitory effects on virus replication, both in vitro and in the Syrian hamster model, of an array of drugs that are approved for other diseases. We evaluated only one dose and route for each drug, which we selected based on previous studies using rodent models to examine treatments for other pathogens or diseases (17, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) , or by using a dose conversion calculation from human to animal dose based on body weight; accordingly, this is a limitation of this study, because other dosages may result in different efficacy. Although some of the drugs did not show an effect in vitro and/or in the hamster model, the information obtained here may still be important for future drug candidate analyses for pandemic viruses.

Here, we showed that administration of favipiravir, either prophylactically or therapeutically, inhibits SARS-CoV-2 replication in the hamster infection model. Favipiravir is a prodrug of a nucleotide analog which interferes with the RNA-dependent RNA polymerase, acting as a pseudo purine (42, 43) . Favipiravir was first approved as an antiinfluenza virus drug in Japan, and since then has been shown to be effective against many other RNA viruses, including Ebola virus, Lassa virus, and Sudan virus in animal models (44) (45) (46) (47) ; this suggests its broad-spectrum and more general utility against RNA viruses, including novel viruses that may emerge in the future.

A recent pharmacokinetic study showed that favipiravir at a single dose of 25 mg/ animal, which is comparable to the dosing used in our study (24 to 28 mg/animal/ administration based on body weight), gave concentrations of 135 mg/mL and 81.3 mg/g in the plasma and lungs, respectively, at 5 h post-administration, although the concentration in plasma exponentially decreased to 1.43 mg/mL at 12 h postadministration (13) . Based on the EC 50 values in our study (130 mM and 320 mM in VeroE6/TMPRSS2 cells and Calu-3 cells, respectively; corresponding to 20.4 mg/mL and 50.3 mg/mL, respectively) and the EC 50 value of 61.88 mM (corresponding to 9.7 mg/ mL) with VeroE6 cells from a previous study (21) , the in vivo effectiveness in hamsters and that of in vitro assays seems to be consistent. Notably, in clinical trials, favipiravir administration to humans (1,800 mg twice/day on day 1 followed by 800 mg twice/day for 13 days) resulted in mean daily trough levels of .20 mg/mL without causing remarkable adverse effects (48) . Pharmacokinetics in humans differ from those in hamsters, and favipiravir levels in human respiratory organs remain to be examined further; however, these results suggest that favipiravir treatment could be a safe and feasible option for COVID-19 therapy.

Remdesivir is also a broad-spectrum prodrug of a nucleotide analog. In terms of COVID-19 treatment, the WHO Solidarity trial found that remdesivir had little to no effect on mortality in hospitalized patients when administered late (49); however, several randomized clinical trials have suggested that remdesivir can shorten recovery time and/or improve prognosis (50) . Also, notably, remdesivir treatment of COVID-19 patients with deficient humoral immunity reduced sub-genomic viral RNA levels in their respiratory tracts by several log-fold, thereby demonstrating its in vivo efficacy in humans (51) . Although its antiviral effects on SARS-CoV-2 and Ebola virus have been shown in nonhuman primate models (52, 53), remdesivir did not significantly reduce SARS-CoV-2 replication in our hamster model; this may be partly explained by the previous finding that remdesivir is rapidly metabolized in rodents due to high serum esterase activity (54, 55) . In contrast, Yuan et al. reported that intraperitoneal administration of remdesivir (15 mg/kg) in a therapeutic regimen reduced viral load in the lungs, underscoring the importance of testing drugs in several different animal models and using different administration routes (15) . We did, however, find that GS-441524, a metabolite of remdesivir, effectively inhibited SARS-CoV-2 replication in hamsters. GS-441524 is currently available only as a research compound; however, its safety and effectiveness have been experimentally proven for treating feline infectious peritonitis caused by feline coronavirus infection (28, 29) . In previous studies, GS-441524 was administered to cats via the intravenous and/or subcutaneous route (28, 29) , and remdesivir was administered intravenously to nonhuman primates (52, 53) . Therefore, in this study, the drugs were subcutaneously administered to hamsters. However, a recent pharmacokinetic study in mice demonstrated that oral or intravenous administration of GS-441524 led to comparable GS-441524 plasma levels and resulted in distribution of the drug in the lungs and liver (56) . Of note, a phase I clinical trial of orally administered GS-441524 for COVID-19 therapy has been reported in July 2021, although the data are preliminary and the number of participants in the study was limited (https://clinicaltrials.gov/ct2/show/study/NCT04859244; https://osf.io/am5s8/ as a preprint manuscript). These findings support the feasibility of GS-441524 administration to humans. Both remdesivir and GS-441524 are detectable in plasma after administration and are cell-membrane permeable, whereas the active form that they are converted to (i.e., the triphosphate analog GS-443902) exists only within cells (57) . Recent studies have shown that GS-441524 has inhibitory potency comparable to that of remdesivir on SARS-CoV-2 replication in several cell lines, including VeroE6 cells and human primary cells (23, 58) , and that its antiviral activity in those cells correlates with the intracellular concentration of GS-443902 converted from either remdesivir or GS-441524 (23) . Moreover, recent pharmacokinetic and pharmacodynamic studies of remdesivir in humans showed that the concentration of intravenously injected remdesivir declines rapidly, with a half-life of ;1 h in plasma, followed by an increase in GS-441524 concentration that persists for much longer, with a half-life range of 13 to 31 h (57, 59, 60) . These findings suggest that GS-441524 shows promise as a therapeutic option to treat SARS-CoV-2 infection.

In this study, we found that co-administration of favipiravir and GS-441524 effectively suppressed SARS-CoV-2 replication in hamsters, reducing the viral load in the lungs by 2 log-fold with low (10 PFU) or high (1,000 PFU) titer virus challenge, although the titers in the nasal turbinate were less affected. Under some experimental conditions, the inhibitory effects of dosage on virus replication were more prominent with the high-titer virus challenge (i.e., virus loads in the lungs with favipiravir therapeutic administration [ Fig. 1B] ; in the nasal turbinates with favipiravir/GS-441524 therapeutic administration [ Fig. 3B] ). We previously observed that a SARS-CoV-2 inoculation of 10 PFU/animal was sufficient for the virus to replicate efficiently to reach titers similar to those seen in animals infected with 1,000 PFU, and that the growth kinetics were different depending on the challenge titers (Fig. S6) , which may partly explain the apparent contradiction. The virus load reductions in the lungs and nasal turbinates with favipiravir administration (i.e., favipiravir therapeutic administration and 1,000 PFU of challenge virus [ Fig. 1B and C; Fig. 3C and D]) varied to some extent; this variation might be due to the small sample size, however, the mean fold reduction was 1.09 logfold and 1.32 log-fold in the lungs (Fig. 1B and Fig. 3C ) and 1.06 log-fold and 1.47 logfold in the nasal turbinates ( Fig. 1C and Fig. 3D) . Therefore, the difference between the experiments was not substantial.

In this study, body weight change of infected animals was monitored as a clinical marker. However, some caution is required when interpreting these results because, in drug administration models, body weight is affected both by the disease severity caused by the virus infection and by the toxicity of the drug(s); in fact, a previous study has shown that high-dose favipiravir administration causes weight loss in uninfected hamsters (13) . As a result, body weight loss is not necessarily correlated with virus titers in organs (Fig. 3C-E; Fig. S2-4) . Also, body weight loss may not be obvious with lower challenge doses in the hamster SARS-CoV-2 infection model, and the extent of the weight loss may differ between experiments. Administration of the vehicle control to infected animals also may cause variations in body weight changes, depending on the route and amount administered. Pathological analyses in organs would be preferable to evaluate the severity of the disease more precisely.

Favipiravir and GS-441524 in SARS-CoV-2 Hamster Model ® Immunohistochemistry analyses revealed no difference between the numbers of nucleocapsid protein-positive bronchial and alveolar epithelial cells in the vehicle dosage group and those in the the favipiravir/GS-441524 prophylactic/therapeutic coadministration groups (Fig. 4I-K) , whereas the infectious virus load in the lungs was reduced by 2 log-fold with either the prophylactic or therapeutic regimen compared to that of the vehicle dosage group (Fig. 3A) . In contrast, the amount of viral RNA detected by in situ hybridization in the lungs was reduced with co-administration treatment for either regimen (Fig. 4E-G) , demonstrating a better correlation with virus loads in this organ (Fig. 3A) . Intriguingly, prophylactic co-administration more effectively reduced inflammatory cell infiltration into the lungs than did the therapeutic regimen ( Fig. 4A and B) , even though the infectious virus loads in the lungs were similar (Fig. 3A) . These results suggest that pretreatment with these drugs may reduce inflammatory responses in the lungs; further studies would help elucidate the underlying mechanism.

Finally, we showed that in the hamster transmission model, co-administration of GS-441524 and favipiravir to animals prior to exposing them to infected animals provided partial protection from virus airborne transmission (4 of 6 pairs were protected, compared with none of the 6 pairs for the vehicle control group), suggesting the potential of co-administration as a preventive measure. The virus titers in the upper respiratory tract (nasal turbinate) in unprotected animals were not as reduced as those in the lungs (Fig. 5C) , suggesting that those animals may emit viruses for further transmission. Nevertheless, based on our pathological analyses (Fig. 4) , prophylaxis with these drugs should be highly effective at reducing disease severity in unprotected animals. Currently, GS-441524 is only approved for research use; however, as mentioned previously, a phase I clinical trial of GS-441524 as an oral therapy has been recently reported (https://clinicaltrials.gov/ct2/show/study/NCT04859244) which demonstrated that oral administration of GS-441524 to humans achieved better persistence of the drug concentration in plasma compared to IV administration of remdesivir; this suggests that oral administration of GS-441524 could be an option for SARS-CoV-2 treatment in the future. As for parenteral administration of the drug to naive contacts, some situations may be anticipated such as pretreatment of uninfected individuals with cluster infections in nursing homes or hospitalized individuals at high risk of infection due to immunodeficiency.

In conclusion, our findings with the hamster model in this study suggest that the repurposing and co-administration of approved drugs may be an attractive approach to combat COVID-19.

Cells. VeroE6/TMPRSS2 (JCRB 1819) cells were propagated in the presence of 1 mg/mL Geneticin (G418; InvivoGen) and 5 mg/mL plasmocin prophylactic (InvivoGen) in Dulbecco modified Eagle's medium containing 10% fetal calf serum (FCS) and antibiotics. Calu-3 (ATCC HTB-55) cells were maintained in Eagle's minimal essential media (MEM) containing 10% fetal calf serum (FCS) and antibiotics. Cells were incubated at 37°C with 5% CO 2 and regularly tested for mycoplasma contamination using PCR, and were confirmed to be mycoplasma-free.

Virus. SARS-CoV-2 (SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo) was propagated in VeroE6 cells in Opti-MEM I (Invitrogen) containing 0.3% bovine serum albumin and 1 mg of L-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-trypsin/mL in MEM supplemented with 2% FCS at 37°C. The furin cleavage site sequence was confirmed to be intact by deep sequencing of the virus stock (data not shown). SARS-CoV-2 Spike-D614G variant was generated using reverse genetics based on the SARS-CoV-2 WA1 strain at Baric's lab (31) , and was propagated as described above.

Compounds Dosage and virus infection of Syrian hamsters. Four-to-six-week-old Syrian hamsters (female or male) were purchased from Envigo (Indianapolis, IN, USA) or Japan SLC, Inc. (Shizuoka, Japan). For oral administration, compounds were suspended in 0.5% methylcellulose in water and were administered via plastic feeding tubes (18G, 50 mm) with an administration volume of 10 mL/kg. For subcutaneous inoculation, remdesivir and GS-441524 were suspended in 12% SBE-b-CD in water. For intranasal administration, ciclesonide (100 mg/mL) in 100% ethanol was diluted in saline at 1:100 and administered at a volume of 1 mL/kg. For intraperitoneal administration, nafamostat was suspended at 3 mg/mL in saline with an administration volume of 10 mL/kg. Under anesthesia by ketamine-xylazine or isoflurane inhalation, four hamsters per group were intranasally inoculated with 10 or 1,000 PFU/animal of SARS-CoV-2/ UT-NCGM02/Human/2020/Tokyo. Body weights were monitored daily after infection. On day 4 postinfection, animals were euthanized and their lung lobes and nasal turbinates were pooled to determine virus titers by use of plaque assays in VeroE6/TMPRSS2 cells.

Determination of half-maximal effective concentration values. VeroE6/TMPRSS2 cells or Calu-3 cells were seeded in 96-well plates 1 day prior to infection, and were incubated at a multiplicity of infection (MOI) of 0.01 or 0.1, respectively, with SARS-CoV-2 at 37°C for 1 h. The inocula were then replaced with MEM containing 5% FCS and serially diluted drugs, and the cells were incubated at 37°C with 5% CO 2 for 2 days to observe cytopathic effects (CPE).

Determination of half-maximal inhibitory concentration values. VeroE6/TMPRSS2 cells were seeded in 6-well plates 1 day prior to infection, and were incubated with 50 PFU/well of SARS-CoV-2 at 37°C for 1 h. After the inocula were aspirated, 2 mL/well of MEM containing 5% FCS and 1% agarose was layered onto the cells. After incubation at 37°C with 5% CO 2 for 2 days, the cells were fixed with 10% formalin-PBS (phosphate-buffered saline) and the plaques were counted.

Drug combination study. VeroE6/TMPRSS2 cells were seeded in 6-well plates 1 day prior to infection. The cells were infected with virus diluent that resulted in 50 to 100 virus plaques per well. After incubation at 37°C for 1 h, the viral inoculum was removed and the cells were overlaid with MEM containing 1% of agarose and each drug-concentration combination. Relative inhibition of plaque formation (%) was calculated based on plaque number reduction compared that of the well without drugs. A ZIP synergy score was calculated and mapped using the SynergyFinder (v.2.0) application (30) .

Pathological examination. Excised lung tissues were fixed in 10% formalin in PBS and processed for paraffin embedding. The paraffin blocks were cut into 3-mm-thick sections and then mounted on silane-coated glass slides. One section from each tissue sample was stained using a standard hematoxylin and eosin procedure; other sections were processed either for in situ hybridization using an RNA scope 2.5 HD Red Detection kit (Advanced Cell Diagnostics, Newark, California) with an antisense probe targeting the nucleocapsid gene of SARS-CoV-2 (Advanced Cell Diagnostics) or for immunohistochemical staining with a rabbit polyclonal antibody for SARS-CoV virus nucleocapsid protein (Prospec; ANT-180). Specific antigen-antibody reactions were visualized by means of 3,39-diaminobenzidine tetrahydrochloride staining using the Dako Envision system (Dako Cytomation). To evaluate comprehensive histopathological changes, lung tissue sections were scored based on pathological changes. Scores were determined based on the percentage of inflammation area for each section of the five lobes collected from each animal in each group by using the following scoring system: 0, no pathological change; 1, affected area (#10%); 2, affected area (,50%, .10%); 3, affected area ($50%). An additional point was added when pulmonary edema and/or alveolar hemorrhage was observed. The total score for the five lobes is shown for each animal in Table S3 .

Virus transmission study in Syrian hamsters. Naive hamsters (exposed animals) were administered favipiravir (300 mg/kg) and/or GS-441524 (25 mg/kg) or vehicle control twice/day (days -1 to 3 post-exposure; n = 6/group); another group of animals (infected animals) was inoculated with 1,000 PFU of SARS-CoV-2 Spike-D614G virus. One day after initiating drug treatment of the exposed animals and virus inoculation of the infected group, each exposed animal was paired with one of the infected animals with a 5-cm gap between their cages in an isolator unit (Showa Science). Air supply and exhaust for each isolator unit was filtered by high efficiency particulate air (HEPA) filters to prevent cross-contamination, resulting in unidirectional airflow directed from the 'infected animal' to the 'exposed animal' in each isolator unit. The infected animals and the exposed animals were euthanized to titrate the virus loads in the nasal turbinate and lungs on day 4 postinfection and day 4 post-exposure, respectively. For virus titration, whole lobes of the lungs were harvested, pooled, weighed, and homogenized. For each lung or nasal turbinate sample, 1 mL of medium was added and, after homogenization in the media, 100 mL of the homogenate was subjected to titration in plaque assays. The detected plaque numbers were then divided by the weight of the organ. The detection limit of the virus in this study was 10 PFU/ organ.

Statistics. Statistical analysis was performed in GraphPad Prism 8 using a one-way ANOVA corrected by using Dunnett's test for multigroup comparison or an unpaired t test for two groups.

Data availability. All study data are included in the article. 

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

A prospective, randomized, openlabel trial of early versus late favipiravir therapy in hospitalized patients with COVID-19

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for the treatment of Covid-19: final report

Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials

Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cellderived cardiomyocytes

Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic Coronavirus Disease

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

Uncovering flexible active site conformations of SARS-CoV-2 3CL proteases through protease pharmacophore clusters and COVID-19 drug repurposing

The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies

Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Favipiravir (T-705) protects against Nipah virus infection in the hamster model

Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters

Protective effects of alanylglutamine supplementation against nelfinavir-induced epithelial impairment in IEC-6 cells and in mouse intestinal mucosa

Chloroquine is therapeutic in murine experimental model of paracoccidioidomycosis

Effect of proparacaine in a mouse model of allergic rhinitis

Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo

Development and validation of an Onchocerca ochengi microfilarial hamster model for onchocerciasis drug screens

Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)

The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Favipiravir and GS-441524 in SARS-CoV-2 Hamster Model ®

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Use of favipiravir to treat Lassa virus infection in macaques

Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

Postexposure protective efficacy of T-705 (Favipiravir) against Sudan virus infection in guinea pigs

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): a structured summary of a study protocol for a randomised controlled trial

Repurposed antiviral drugs for COVID-19: interim WHO Solidarity trial results

Recent progress of antiviral therapy for coronavirus disease 2019

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment

Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor

Remdesivir metabolite GS-441524 effectively inhibits SARS-CoV-2 infection in mouse models

Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis

Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects

We thank Aaron Balogh and Alexander Karasin for technical assistance, and Susan Watson for scientific editing. This research was supported by a grant (HHSN272201400008C to Y. We declare no competing interests.